Journal
Inflammatory bowel diseases
Publication Date
5-17-2021
Volume
27
Issue
6
First Page
816
Last Page
825
Document Type
Open Access Publication
DOI
10.1093/ibd/izaa199
Rights and Permissions
Gary R Lichtenstein, MD, Gerhard Rogler, MD, PhD, Matthew A Ciorba, MD, Chinyu Su, MD, Gary Chan, PharmD, Ronald D Pedersen, MS, Nervin Lawendy, PharmD, Daniel Quirk, MD, MPH, MBA, Chudy I Nduaka, DVM, PhD, Andrew J Thorpe, PhD, Julian Panés, MD, PhD, Tofacitinib, an Oral Janus Kinase Inhibitor: Analysis of Malignancy (Excluding Nonmelanoma Skin Cancer) Events Across the Ulcerative Colitis Clinical Program, Inflammatory Bowel Diseases, Volume 27, Issue 6, June 2021, Pages 816–825, https://doi.org/10.1093/ibd/izaa199. © 2020 Crohn’s & Colitis Foundation. Published by Oxford University Press on behalf of Crohn’s & Colitis Foundation. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com.
Recommended Citation
Lichtenstein, Gary R; Rogler, Gerhard; Ciorba, Matthew A; Su, Chinyu; Chan, Gary; Pedersen, Ronald D; Lawendy, Nervin; Quirk, Daniel; Nduaka, Chudy I; Thorpe, Andrew J; and Panés, Julian, "Tofacitinib, an oral Janus kinase inhibitor: Analysis of malignancy (excluding nonmelanoma skin cancer) events across the ulcerative colitis clinical program." Inflammatory bowel diseases. 27, 6. 816 - 825. (2021).
https://digitalcommons.wustl.edu/oa_4/921
Additional Links
Supplemental material is available for this article at publisher site.
